Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDOSTAR: Dostarlimab for Prevention of Second Primary Cancer
NCT05855811Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in Second Primary Cancer (SPM), sponsored by Centre Léon Bérard. Started Jul 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
Second Primary Cancer (SPM)
Beyond the preview
Go deeper on NCT05855811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855811.